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Abstract
Objective. Few data exist on the use of anti-TNF drugs for AS during routine clinical use in the UK. This
report describes an improvement in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Bath
Ankylosing Spondylitis Functional Index (BASFI) after 6 months of therapy in 261 patients enrolled in a
national prospective observational register.
Methods. The British Society for Rheumatology Biologics Register (BSRBR) recruited patients starting
anti-TNF therapy for AS between 2002 and 2006. Multivariable linear regression models were used to
estimate the predictors of absolute improvement in BASDAI and BASFI at 6 months. Covariates included
age, gender, disease duration, baseline BASDAI and BASFI, presence of raised inflammatory markers
(defined as twice the upper limit of normal) and DMARD therapy.
Results. The cohort was young (median age 43 years) and 82% were males. Median baseline BASDAI
was 7.6 and BASFI 7.9. At 6 months, the mean improvements in BASDAI and BASFI were 3.6 and 2.6U,
respectively; 52% reached a BASDAI50. Patients with raised inflammatory markers at the start of therapy
had a 0.9-U (95% CI 0.2, 1.5) better improvement in BASDAI compared with those without. Lesser
responses were seen in those with higher baseline BASFI scores. Women had a 1.1-U (95% CI 0.3,
2.0) greater improvement in BASFI at 6 months, as did those who were receiving concurrent DMARD
therapy [0.9U (95% CI 0.2, 1.7)].
Conclusions. The majority of patients receiving anti-TNF therapy for AS during routine care demonstrated
an improvement in disease activity. Raised inflammatory markers at the start of therapy predicted a
greater improvement in BASDAI, identifying a group of patients who may be more responsive to
anti-TNF therapies, although the results were not confined to this group.
Key words: Anti-TNF, Etanercept, Infliximab, Adalimumab, Ankylosing spondylitis, Treatment response,
Treatment effectiveness, Disability.
Introduction
AS is an inflammatory disorder mainly affecting the axial
skeleton, although peripheral joints and extra-articular
tissue may also be involved [1]. The cytokine TNF-a is
regarded as an important mediator in the disease process
and raised levels of TNF have been found in the SI joints of
patients with AS [2]. Anti-TNF has been used as a suc-
cessful treatment in RA for several years and more
recently was shown to be effective in AS [3–5]. There
are currently three anti-TNF agents approved for the treat-
ment of AS: infliximab and adalimumab, both mAbs
directed against TNF, and etanercept (ETA), a soluble
p75 TNF receptor fusion protein. Guidelines for the use
of anti-TNF agents in patients with AS in the UK were
published in July 2004 by the British Society for
Rheumatology (BSR) [6]. These guidelines state that
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Etreatment with anti-TNF agents may be appropriate for
those patients who (i) satisfy the modified New York cri-
teria for the diagnosis of AS [7], (ii) have failed conven-
tional treatment with two or more NSAIDs, and (iii) have
active disease as defined by a Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI) [8] score
54 and spinal pain score 54cm, measured on a 10-cm
visual analogue scale. The recommended doses are eta-
nercept 25mg twice weekly or 50mg once weekly, inflix-
imab 5mg/kg at 0, 2, 6 weeks and 6–8 weekly thereafter,
adalimumab 40mgs.c. every 2 weeks. Unlike RA [9], there
are no specific recommendations regarding co-therapy
with MTX.
Randomized controlled trials (RCTs) have shown all
three anti-TNF agents to be efficacious. However, patient
selection in clinical trials is not always representative of
prescribing guidelines and clinical practice in individual
countries. Data from observational studies of response
to anti-TNF treatment in AS have previously been pub-
lished [10–15], although robust conclusions are often pre-
vented by the small sample sizes of these studies. A large,
open-label Phase IIIb trial of adalimumab identified that
factors including younger age, higher CRP concentration
and HLA-B27 positivity were associated with good clini-
cal response, defined as either a 50% improvement
in the BASDAI (BASDAI50), a 40% improvement in the
Assessments of SpondyloArthritis International Society
criteria (ASAS40) or ASAS partial remission [16]. Few stu-
dies have looked specifically at the factors associated
with improvements in function.
The aims of this study were (i) to evaluate the effective-
ness of anti-TNF drugs within a UK cohort of AS patients
receiving anti-TNF therapy during routine clinical care by
assessing changes in measurements of disease activity
and functional ability 6 months after starting treatment;
and (ii) to identify factors, measured at the start of treat-




The subjects for this analysis are participants in a large
prospective observational study, the British Society for
Rheumatology Biologics Register (BSRBR). This register
was established in 2001, with the primary aim of monitor-
ing the long-term safety of biologic agents in RA [17].
However, between 2002 and 2006, the register also cap-
tured data on a small cohort of biologic naı ¨ve AS patients
starting treatment with their first anti-TNF agent.
Data
Upon initiation of anti-TNF treatment, the patient’s rheu-
matologist or rheumatology nurse specialist completes a
baseline questionnaire and forwards this to the BSRBR.
This includes details on demographics, disease activity
(28-active joint count, ESR or CRP), previous and current
anti-rheumatic therapy and comorbidity. Follow-up ques-
tionnaires are completed every 6 months and details of
changes to anti-rheumatic therapies, disease activity and
functional status are captured. As the BSRBR was initially
designed to collect information on patients with RA, early
questionnaires did not include specific AS disease activity
measures. In September 2003, the baseline questionnaire
was amended to include the BASDAI and the Bath
Ankylosing Spondylitis Functional Index (BASFI) [18]. To
reduce the amount of missing data, physicians who had
recruited patients before this date were contacted to for-
ward results of missing BASDAIs and BASFIs, where
available.
Analysis
Analysis was performed using Stata version 9.2 (Stata,
2006, College Station, TX, USA). Baseline characteristics
were compared among the three anti-TNF agents using
non-parametric descriptive statistics. The primary out-
come measure was absolute change in BASDAI between
baseline and 6-month assessment for the whole cohort.
Secondary measures included the absolute change in
BASFI between baseline and 6-month assessment. To
represent UK prescribing guidelines, the final mea-
surement assessed the proportion of patients who
achieved at least 50% improvement in BASDAI
(BASDAI50) after 6 months of treatment, the benchmark
by which UK physicians are advised to make decisions on
response [6].
Factors associated with the absolute change in BASDAI
and BASFI in the first 6 months were modelled using linear
regression. Covariates included age, gender, disease
duration, baseline BASDAI and BASFI, the presence of
raised inflammatory markers (defined as ESR>25mm/h
and/or CRP>20mg/l), concurrent DMARD therapy,
smoking status, year when anti-TNF therapy was started
and the anti-TNF drug used. Factors with significance at
P40.2 in univariate models were entered into a multivari-
able model. Similarly, a multivariable logistic regression
model was developed to identify factors associated with
achieving a BASDAI50 response at 6 months, using the
same covariates.
Ethical approval
Ethical approval for the BSRBR was obtained from the
Central Office for Research Ethics Committees of the




Till July 2007, 261 patients with AS were registered with
the BSRBR and had completed both a baseline and
6-month BASDAI. Baseline characteristics are presented
in Table 1. As would be expected in a cohort of patients
with AS, subjects were young with a male to female ratio
of 4:1. The median disease duration was 13 years. The
median BASDAI was 7.6 [interquartile range (IQR) 6.4–8.6]
and the median BASFI was 7.9 (IQR 6.2–8.9), indicating
severe disease. In general, subjects treated with each of
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more patients starting infliximab or adalimumab were
receiving concurrent DMARDs. Patients receiving inflixi-
mab also tended towards longer disease duration,
although this did not reach statistical significance. The
median dose of infliximab was 4.9 (IQR 4.0–5.0) mg/kg,
although 25% of the cohort was receiving 3mg/kg, the
licensed starting dose for RA.
Response. The mean improvement in BASDAI after 6
months was 3.6U and 52% of patients achieved a
BASDAI50 (Table 2). The mean improvement in BASFI
after 6 months was 2.6U. Improvement in both ESR
[mean improvement 27.3mm/h (95% CI 23.4, 31.3)] and
CRP level [mean improvement 25.3mg/l (95% CI 18.2,
32.5)] was also observed at 6 months.
Results of the multivariable linear regression analysis of
factors associated with change in BASDAI at 6 months are
shown in Table 3. The strongest predictors were baseline
BASDAI score, with a 0.69U better improvement for each
unit increase in baseline BASDAI score, and the presence
of raised inflammatory markers (ESR and/or CRP) at the
start of therapy, with a 0.89 greater improvement among
those with raised baseline indices. However, patients with
the higher baseline BASFI scores demonstrated less
improvement in BASDAI. The use of concurrent
DMARDs was not significantly associated with absolute
improvements in BASDAI.
Similar results were found in a logistic regression ana-
lysis, looking at predictors of a 50% improvement in
BASDAI (BASDAI50) (Table 4). In addition, patients were
more likely to achieve a BASDAI50 when anti-TNF drugs
were taken in combination with DMARDs. When the
effects of concurrent DMARD therapy on BASDAI50
were stratified by anti-TNF agent, concurrent DMARDs
appeared to only be important in patients receiving inflix-
imab (50% response in co-therapy vs 26% monotherapy;
P=0.016). Small numbers prevented comparison
between the anti-TNF drugs.
Different factors were associated with an improvement
in BASFI at 6 months (Table 5). At baseline, the median
baseline BASFI in males was 7.9 (IQR 6.3–8.9) and in
females 7.7 (IQR 6.1–9.2). The median baseline BASFI in
patients not on concurrent DMARDs was 7.9 (IQR 6.4–8.9)
and in those receiving DMARDs 7.6 (IQR 5.9–8.7). In a
multivariate model, the strongest independent predictors
of improvement in BASFI were being female, higher base-
line BASFI and concurrent DMARD use, all favouring a
greater improvement in BASFI. Improvements in BASFI
were not related to baseline BASDAI.
Discussion
This study evaluated the short-term effectiveness of
anti-TNF in AS. The results are in agreement with the
results from RCTs, indicating that anti-TNF therapy is an
effective treatment option for patients with AS. Both the
BASDAI and BASFI scores improved after 6 months of
treatment, and more than half of the subjects achieved a
BASDAI50 response.
Unlike the RCTs for anti-TNF drugs in AS, this study
evaluated treatment of patients within the context of UK
prescribing guidelines and enrolled many patients who
could have been excluded from previous trials, for rea-
sons including concurrent DMARD therapy or comorbid-
ities. However, the BSRBR was not initially designed for
analysis of effectiveness of anti-TNF drugs in AS patients.
TABLE 1 Baseline characteristics
Anti-TNF treatment All Etanercept Infliximab Adalimumab P-value
No. of subjects 261 148 (57) 93 (36) 20 (7)
Age, years 43 (37–51) 43 (35–51) 43 (37–51) 44 (39–56) 0.70
Male, n (%) 213 (82) 124 (84) 70 (75) 19 (95) 0.07
Disease duration, years 13 (6–21) 12 (6–20) 15 (6–25) 15 (10–19) 0.40
BASDAI, U 7.6 (6.4–8.6) 7.7 (6.6–8.6) 7.5 (5.6–8.5) 7.6 (6.7–8.3) 0.31
BASFI, U 7.9 (6.2–8.9) 8.0 (6.0–8.9) 7.7 (6.0–8.9) 7.9 (6.9–8.6) 0.77
ESR, mm/h 31 (14–63) 30 (14–67) 34 (14–62) 27 (11–51) 0.47
CRP, mg/l 23 (9–55) 26 (8–57) 23 (12–49) 16 (9–26) 0.56
Smoking status, n (%)
Never 85 (33) 45 (30) 32 (35) 8 (40)
Previously 81 (31) 43 (29) 34 (37) 4 (20) 0.27
Currently 94 (36) 60 (41) 26 (28) 8 (40)
DMARD at start of anti-TNF
therapy, n (%)
116 (44) 55 (37) 50 (54) 11 (55) 0.03
MTX 90 (35) 40 (27) 40 (43) 10 (50) 0.01
SSZ 37 (14) 19 (13) 16 (17) 2 (10) 0.55
>1 DMARD 21 (8) 9 (6) 10 (11) 2 (10) 0.11
NSAID treatment, n (%) 189 (72) 106 (72) 69 (74) 14 (70) 0.88
Steroid treatment, n (%) 38 (15) 22 (15) 13 (14) 3 (15) 0.98
Values are given as median (IQR), unless otherwise specified.
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measures on AS patients and, therefore, may have
excluded patients in whom BASDAI and BASFI were not
collected by the treating physician. This exclusion may
have threatened the external validity of our results.
Although the baseline characteristics of the analysed
cohort were generally in agreement with other published
cohorts of AS patients, more patients were treated con-
currently with DMARDs, in this study, than found in previ-
ous studies. It is not clear whether this is a reflection of
exclusions from clinical trials or of differences in manage-
ment within the UK. Finally, we did not have detailed
data on non-biologic anti-rheumatic drug doses, such as
NSAIDS or steroids, past the first visit and, therefore, are
TABLE 2 Response to anti-TNF treatment at 6 months
Anti-TNF treatment All Etanercept Infliximab Adalimumab P-value
n 261 148 93 20
BASDAI at start of
therapy, mean (S.D.)
7.3 (1.8) 7.4 (1.7) 7.0 (2.0) 7.3 (1.7) 0.31
BASDAI at 6 months,
mean (S.D.)




3.6 (3.9, 3.3) 4.1 (4.6, 3.8) 2.9 (3.4, 2.4) 2.5 (3.6, 1.4) 0.0002
Achieving BASDAI50
response, n (%)
136 (52) 93 (64) 36 (39) 7 (35) P<0.01
BASFI at the start of
therapy, mean (s.d.)
7.3 (2.2) 7.4 (2.0) 7.1 (2.4) 7.6 (1.7) 0.77
BASFI at 6 months,
mean (s.d.)




2.6 (3.0, 2.2) 3.1 (3.6, 2.7) 1.7 (2.3, 1.1) 3.4 (4.9, 1.9) 0.0028
ESR at the start of
therapy, mean
(s.d.), mm/h
39.4 (29.3) 40.6 (31.2) 39.6 (27.6) 30.9 (22.6) 0.21
ESR after 6 months
of therapy, mean
(s.d.), mm/h




27.3 (31.3, 23.4) 27.5 (33.1, 21.8) 26.9 (33.2, 20.7) 28.3 (37.5, 19.1) 0.48
CRP at the start of
therapy, mean
(s.d.), mg/l
35.3 (35.1) 36.9 (35.12) 35.5 (36.6) 24.7 (26.4) 0.36
CRP after 6 months
of therapy,
mean (s.d.), mg/l




25.3 (32.5, 18.2) 25.1 (35.8, 14.4) 29.0 (40.0, 18.0) 8.6 (20.6, +3.3) 0.46
TABLE 3 BASDAI change at 6 months—linear regression models
Covariates Univariate, coefficient (95% CI) Multivariate,
a coefficient (95% CI)
Age, decades 0.04 (0.01, 0.07) 0.02 (0.01, 0.05)
Female 0.48 (1.28, 0.32) 0.32 (1.08, 0.44)
Disease duration 0.02 (0.01, 0.05) 0.01 (0.04, 0.03)
Baseline BASDAI (per unit increase) 0.51 (0.67, 0.35) 0.69 (0.90, 0.48)
Baseline BASFI (per unit increase) 0.12 (0.28, 0.03) 0.26 (0.08, 0.45)
Raised inflammatory markers 0.71 (1.35, 0.07) 0.89 (1.53, 0.24)
NSAID treatment at baseline (yes/no) 0.25 (0.95, 0.01) –
MTX treatment at baseline (yes/no) 0.05 (0.70, 0.61) –
Any DMARD treatment at baseline (yes/no) 0.12 (0.75, 0.51) –
Steroid treatment at baseline (yes/no) 0.16 (1.05, 0.72) –
Smoking—never Reference –
Smoking—previous 0.46 (0.31, 1.24) –
Smoking—current 0.46 (1.21, 0.28) –
aMultivariable analysis adjusted additionally for calendar year of starting therapy and anti-TNF drug.
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results.
The strongest predictors of improvement in disease
activity were raised inflammatory markers at the start of
therapy and the higher baseline levels of disease activity,
the latter of which may represent regression to the mean,
whereas a higher BASFI score was associated with a
lesser response. In our study, improvement in disease
activity was not associated with age at the start of therapy
or disease duration. A smaller observational study (n=99)
of infliximab- and etanercept-treated AS patients found
that raised CRP, raised baseline BASDAI and lower base-
line BASFI were predictive of achieving a BASDAI50 after
12 weeks of treatment [12]. Another study of 22 patients
receiving infliximab found that those achieving an ASAS20
response at 1 year had higher CRP at baseline than
non-responders [11], and that CRP did not correlate
with BASDAI score at baseline. Further analysis of
data collected during a Phase III clinical trial of ETA [19]
and a Phase IIIb trial of adalimumab [16] found similar
results.
In the BSRBR, 65% of subjects had raised inflamma-
tory markers at baseline, and this was predictive of
greater improvement in BASDAI score at 6 months. It
has previously been found that ESR and CRP do not com-
prehensively represent the disease process in AS [20] and
are not currently included in the BSR guidelines for pre-
scribing anti-TNF in AS [6]. Although the effect of raised
inflammatory markers was greater than that of baseline
BASDAI score in predicting response, the decision to ini-
tiate anti-TNF therapy in AS should not be based solely
on inflammatory markers, as 47% of the subjects
TABLE 5 BASFI change at 6 months—linear regression models
Covariates Univariate, coefficient (95% CI) Multivariate,
a coefficient (95% CI)
Age, decades 0.03 (0.01, 0.06) 0.02 (0.01, 0.06)
Female 0.83 (1.75, 0.09) 1.11 (1.96, 0.26)
Disease duration 0.03 (0.00, 0.07) 0.03 (0.01, 0.07)
Baseline BASDAI (per unit increase) 0.22 (0.42, 0.03) 0.10 (0.14, 0.34)
Baseline BASFI (per unit increase) 0.35 (0.52, 0.17) 0.34 (0.57, 0.12)
Raised inflammatory markers 0.64 (1.42, 0.14) 0.50 (1.23, 0.23)
NSAID treatment at baseline (yes/no) 0.36 (1.18, 0.46) –
MTX treatment at baseline (yes/no)
b 0.23 (1.06, 0.61) 0.69 (1.48, 0.09)
DMARD treatment at baseline (yes/no)
b 0.50 (1.26, 0.26) 0.94 (1.65, 0.23)
Steroid treatment at baseline (yes/no) 0.10 (1.13, 0.94) –
Smoking—never Reference Reference
Smoking—previous 0.58 (0.34, 1.49) 0.34 (0.54, 1.22)
Smoking—current 0.82 (1.69, 0.05) 0.48 (1.32, 0.35)
aMultivariable analysis, adjusted additionally for calendar year of starting therapy and anti-TNF therapy.
bMultivariate model
run twice: once with MTX and then again with any DMARD as covariates.
TABLE 4 BASDAI50 response at 6 months—logistic regression models
Covariates Univariate, OR (95% CI) Multivariate,
a OR (95% CI)
Age, decades 0.97 (0.95, 0.99) 0.98 (0.95, 1.01)
Female 1.20 (0.64, 2.26) 1.25 (0.58, 2.69)
Disease duration 0.98 (0.96, 1.01) 1.00 (0.96, 1.03)
Baseline BASDAI (per unit increase) 1.09 (0.95, 1.24) 1.30 (1.04, 1.62)
Baseline BASFI (per unit increase) 0.94 (0.80, 1.03) 0.78 (0.64, 0.99)
Raised inflammatory markers 1.40 (0.84, 2.32) 2.02 (1.05, 3.87)
NSAID treatment at baseline (yes/no) 1.24 (0.72, 2.13) –
MTX treatment at baseline (yes/no)
b 1.48 (0.89, 2.49) 2.23 (1.15, 4.52)
Any DMARD treatment at baseline (yes/no)
b 1.56 (0.95, 2.55) 2.15 (1.11, 4.15)
Steroid treatment at baseline (yes/no) 1.01 (0.51, 2.00) –
Smoking—never Reference Reference
Smoking—previous 0.56 (0.30, 1.03) 0.84 (0.39, 1.84)
Smoking—current 1.04 (0.58, 1.88) 1.34 (0.63, 2.86)
aMultivariable analysis, adjusted additionally for calendar year of starting therapy and anti-TNF agent.
bMultivariate model run
twice: once with MTX and then again with any DMARD as covariates.
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a BASDAI50 response. Although inflammatory markers
may not correlate with disease severity, they may reflect
an increased activity of cytokine-mediated inflammatory
cells that will respond to anti-TNF therapy. Therefore,
raised inflammatory markers may identify a group of AS
patients with active and reversible disease, as opposed to
long-standing chronic damage. Another possible explana-
tion for this finding is that increased ESR and CRP may
correlate with peripheral arthritis and extra-articular invol-
vement in patients with AS. While the role of peripheral
symptoms was not examined in this study, the beneficial
action of anti-TNF drugs outside the axial skeleton may be
responsible for the observed improvements in both
BASDAI and BASFI scores.
Subjects with higher BASFI score at the start of therapy
were less likely to see an improvement in BASDAI after 6
months. Similar results have previously been found in AS,
where lower BASFI predicted a BASDAI50 response [12],
and in RA, where lower HAQ scores were associated
with response and remission [21]. Interestingly, a small
study in PsA found that BASFI scores correlated more
with FM signs and symptoms and fatigue than with
radiological spinal involvement [22], suggesting that
higher BASFI scores may also reflect long-term damage,
chronic pain and other disability, which would be less
responsive to anti-TNF therapy. This point aside, we
still observed significant improvements in BASFI in this
study.
Nearly 50% of patients in this study were receiving con-
current DMARDs, primarily MTX. Unfortunately, it was not
known why these patients were receiving concurrent
DMARDs (i.e. for peripheral arthritis or because of the
benefits of co-prescription with anti-TNF seen in RA [23,
24]). DMARD use was not strongly associated with abso-
lute change in BASDAI but was associated with achieving
a BASDAI50 response, likely indicating that patients were
more likely to cross the BASDAI50 threshold if they were
receiving concurrent DMARD. A Norwegian study [15] did
not find MTX to be a predictor of drug survival in AS,
unlike their findings in both RA and PsA, suggesting that
the effects of concurrent MTX on disease activity in
patients with AS may be different.
This is the first study to identify predictors of improve-
ment in function, measured using the BASFI. Unlike
disease activity, we found a strong association
between gender and improvement in function, with a
significantly greater improvement in women. Concurrent
DMARDs were also found to be a significant predictor of
improvement in function, more so than that seen for
BASDAI.
Although it was not the aim of this study to directly
compare the different anti-TNF drugs, we did observe
some differences. Small numbers in some groups pre-
vented further adjustment in the analysis and therefore,
this finding should be interpreted with some caution.
Although it is difficult to compare results between clinical
trials, a difference in efficacy between the three drugs was
not suggested from the results of the major RCTs of
anti-TNF in AS [3–5], with all studies finding an ASAS20
response in 60% of patients. It is not clear why one drug
should perform better during ‘real world’ use. However, in
this study, patients were not randomized to their anti-TNF
therapies, and factors that may have influenced the phy-
sicians’ decision to treat may also have influenced the
patient’s response. Perhaps, most importantly, all drugs
were not equally available throughout the study period;
etanercept was not available between 2001 and 2003
due to a worldwide shortage and adalimumab was not
available until 2004. During the early years of this study,
more patients were receiving infliximab as their first
anti-TNF agent. These earliest patients were likely to be
those with the most severe disease and, therefore, may
have had a different response from those recruited later,
although an analysis that restricted the patients to those
recruited after 2003 found similar results. In addition, only
70% of subjects treated with infliximab were receiving the
recommended dose of 5mg/kg, with 25% receiving
the dose of 3mg/kg recommended in RA. Nonetheless,
the influence of unmeasured confounders on this differen-
tial response cannot be discounted based on the results
of this observational study and further observations are
warranted.
Conclusions
Anti-TNF therapy is very effective in AS, with improvement
in both disease activity and functional scores after 6
months of therapy. While study design prevents definitive
conclusions, the results of this study suggest predictors of
response. Baseline-raised ESR or CRP may identify a
group of patients who are more responsive to anti-TNF
therapy. Concurrent DMARD treatment was not found to
be a significant predictor of improvement in disease activ-
ity, but was associated with improvement in function.
Further assessment of observational datasets beyond
6 months is warranted to study the benefits of these
agents.
Rheumatology key messages
. Anti-TNF therapy during routine clinical use
improves disease activity and functional impairment
in patients with AS.
. Raised inflammatory markers are a strong predictor
of treatment response.
. Concurrent DMARD therapy improves functional
impairment, but its use is not associated with
improvement in disease activity.
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